Air quality concerns linger in the wake of steel plant explosion in Pennsylvania
The Allegheny County Health Department announced that mobile air units provided by the state and Carnegie Mellon University will be stationed in the Mon Valley where the plant is Thursday and Friday. The county said these measures are part of its ongoing investigation into Monday's explosion at Clairton Coke Works.
The county said the measures go 'well beyond the normal and rigorous regulatory air quality monitoring' and will assess parts of the valley for different types of pollutants such as volatile organic compounds, PM2.5 pollutants and sulfur dioxide.
After Monday's blast, the county health department initially told residents within 1 mile (1.6 kilometers) of the plant to remain indoors and close all windows and doors. The department lifted the advisory after its monitors didn't detect levels of soot or sulfur dioxide above federal standards.
The Allegheny County Medical Examiner's Office also confirmed Thursday that the second person who died in the blast was Steven Menefee, 52, of Clairton. Earlier, the county medical examiner's office identified one of the dead as Timothy Quinn, 39.
U.S. Steel CEO David Burritt said Tuesday the company is working closely with local, state and federal authorities. He would not speculate about the cause of the explosion.
The massive plant along the Monongahela River in Clairton converts coal to coke, a key component in the steelmaking process. The facility is considered the largest coking operation in North America and is one of four major U.S. Steel plants in Pennsylvania.
To make coke, coal is baked in special ovens for hours at high temperatures to remove impurities that could otherwise weaken steel. The process creates what is known as coke gas — a lethal mix of methane, carbon dioxide and carbon monoxide.
The plant has a long history of environmental problems, especially fouling the air in communities nearby the sprawling plant.
In 2018, a Christmas Eve fire damaged pollution-control equipment and led to repeated releases of sulfur dioxide, according to a subsequent lawsuit. The fire prompted Allegheny County to warn residents to limit outdoor activities. Residents said it was hard to breathe for weeks afterward and that the air felt acidic and smelled like rotten eggs. U.S. Steel settled a lawsuit last year with an agreement to spend $19.5 million in equipment upgrades and $5 million on local clean air efforts and programs.
Dr. Deborah Gentile, the medical director of Community Partners in Asthma Care, studied asthma levels after the 2018 fire and found twice as many patients sought medical treatment.
In 2019, U.S. Steel agreed to settle a lawsuit regarding air pollution from Clairton for $8.5 million.
The concerns about air quality also come as the federal Environmental Protection Agency moves to postpone new hazardous air pollution standards for coke plants, like Clairton.
Matthew Mehalik, executive director of the Breathe Project, a public health advocacy group in Pittsburgh, said the regulations were deemed to be almost insignificant to operational costs and would have helped protect the public with air quality monitoring.
The regulation would have required — like is already required at refineries all over the United States — fence-line monitoring for hazardous air pollutants at the Clairton plant, Mehalik said.
That information would have been 'incredibly useful' when the explosion happened on Monday, Mehalik said.
___
Associated Press writer Marc Levy contributed to this report from Harrisburg, Pennsylvania.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles

Associated Press
18 minutes ago
- Associated Press
Death toll in Russian factory fire rises to 24
MOSCOW (AP) — The death toll from last week's fire at an industrial plant in Russia's Ryazan region has risen to 24, with at least another 157 people injured, officials said Monday. The fire broke out Friday at the Elastik plant in Shilovsky district, around 250 kilometers (155 miles) southeast of Moscow. Emergency crews continued searching through debris, Russia's Emergency Situations Ministry said. State news agency RIA Novosti has reported that a gunpowder workshop at the facility caught fire and triggered an explosion. Images released by officials show some of the building reduced to rubble. Investigators are looking into the cause of the fire. Local authorities declared Monday a day of mourning in Ryazan. This was the second deadly incident at the Elastik plant in recent years. In October 2021, 17 people were killed in a blast at a workshop operated by explosives manufacturer Razryad, according to the state news agency Interfax.
Yahoo
4 hours ago
- Yahoo
Philips sharpens AI ultrasound push with $150m manufacturing investment
Philips is investing $150m into expanding a pair of US facilities that manufacture its AI-based ultrasound systems and software. Complementing its existing annual $900m US R&D spend, the medtech giant said the funds' allocation towards expanding its Pennsylvania facility that produces ultrasound systems would support its ongoing growth in the US. According to the company, the site currently manufactures transducers but will also work on the configuration of software used in Philips' ultrasound systems in areas such as cardiovascular and maternal care once the expansion is complete. Philips is also allocating a portion of the funds towards expanding its image-guided therapy facility in Minnesota. The Pennsylvania site expansion is expected to add 24,000ft² of manufacturing space and 40,000ft² of storage. The Minnesota site expansion primarily includes the addition of a new medtech training centre, for which the dimensions were unspecified. According to a GlobalData market model, Philips held a 17% share in the US ultrasound systems market in 2024. The figure puts the company in third place, behind rivals GE Healthcare in poll position and Siemens in second place, with US market share of 34% and 29.4%, respectively. Stating that the manufacturing facility expansions reflect Philips' 'deep commitment' to the US, Philips North America chief region leader Jeff DiLullo said: 'Increasing our manufacturing and R&D capabilities will create jobs and accelerate our ability to deliver better care for more people with innovative AI-enabled solutions.' The facility expansions likely also reflect Philips' efforts to future-proof and insulate its operations from the unpredictable nature of US President Donald Trump's tariffs. In particular, his imposition of tariffs on China has fluctuated dramatically throughout the year. Philips has a number of manufacturing sites in the nation, including R&D innovation centres in Shanghai, Suzhou, and Shenzhen. The Dutch business is not the only medtech company to bolster US manufacturing amid tariffs – Thermo Fisher outlaid $2bn worth of investment in April 2025. In an earnings call with investors following the release of its Q2 2025 financials in July, Philips revealed it was revising its expected China-related tariff impacts for 2025 to between €150m-€200m ($175.2m-$233.6m), down from €250m-€300m ($292.1m-$350.5m) previously. Philips CFO Charlotte Hanneman said work on its planned tariff mitigation actions was 'well underway' and on track: 'We've made solid progress on midterm initiatives, including supplier network and manufacturing location optimisation.' According to GlobalData analysis, the use of AI across healthcare is rapidly advancing, with the market projected to reach a $19bn valuation by 2027. Radiology, including ultrasound, has emerged as one of AI's key application areas – chiefly as a way to drive efficiencies and glean insights that human image evaluation could miss. "Philips sharpens AI ultrasound push with $150m manufacturing investment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
5 hours ago
- Yahoo
PECA Labs' Dr. Arush Kalra Named to Pittsburgh's 40 Under 40 List
Biomedical innovator recognized for advancing next-generation cardiovascular devices and making a lasting impact on patients' lives PITTSBURGH, August 18, 2025--(BUSINESS WIRE)--PECA Labs, a medical device company redefining the field of vascular grafts and valves with durable, polymeric cardiovascular devices designed to fit, grow, and last, today announced that Co-founder and Chief Scientific Officer Dr. Arush Kalra has been named to the Pittsburgh 40 Under 40 list by Pittsburgh Magazine and PUMP. The Pittsburgh 40 Under 40 awards honor high-performing, high-impact professionals who are driving innovation and strengthening the Pittsburgh community through leadership, professional excellence, and service. Dr. Kalra leads PECA Labs' scientific and engineering programs, overseeing clinical research and the development of its proprietary tunable polymeric material platform for cardiovascular implants. Inspired by his mother's battle with cardiovascular disease, he began his career in medicine before pivoting to medical device innovation at the encouragement of a mentor. While pursuing his Master of Science in Biomedical and Medical Engineering at Carnegie Mellon University (CMU), he co-founded PECA Labs with fellow CMU Tartans Doug Bernstein and Jamie Quinterno—without whom, he notes, the venture would not have been possible—to advance the field of cardiothoracic surgery. Since 2018, Dr. Kalra has also served as an adjunct professor at the University of Pittsburgh. "This recognition carries profound meaning, as it brings much-needed attention to the challenges faced by families confronting congenital cardiac defects and chronic adult cardiovascular diseases," said Dr. Kalra. "Our mission is simple yet powerful: to develop innovative cardiovascular devices that provide patients with an improved quality of life and the chance to grow, thrive, and avoid repeat surgeries. It is an honor to be recognized alongside so many talented individuals who are making a meaningful impact in the Pittsburgh community—a place that has given so much to us at PECA Labs and continues to inspire our work." In 2024, PECA Labs opened a new polymeric processing facility near its headquarters in Pittsburgh's Bloomfield neighborhood, adjacent to UPMC Children's Hospital. This expansion brings critical manufacturing in-house, giving the company greater control over production, faster scalability, and the ability to meet growing demand. About PECA Labs PECA Labs is reimagining the field of vascular grafts and valves with durable polymeric cardiovascular devices designed to fit, grow, and last—helping patients avoid repeat surgeries while reducing morbidity and mortality. The company's proprietary technologies, including a controllably expandable graft and low-thrombosis polymeric membrane, are built on a tunable polymer platform that delivers greater durability, customization, and biocompatibility than current cardiovascular implants. PECA's devices resist thrombosis, calcification, and immune response, while offering growth potential, customization, and noninvasive visualization. For more information, visit View source version on Contacts Media Contact: Joe DuraesPazanga Health Communicationsjduraes@ (917) 687-6419